pKLV2-EF1a-BsdCas9-W Citations (12)
Originally described in: A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJ, Iorio F, Pina C, Vassiliou GS, Yusa K Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079. PubMed Journal
Articles Citing pKLV2-EF1a-BsdCas9-W
| Articles |
|---|
| Predicting the mutations generated by repair of Cas9-induced double-strand breaks. Allen F, Crepaldi L, Alsinet C, Strong AJ, Kleshchevnikov V, De Angeli P, Palenikova P, Khodak A, Kiselev V, Kosicki M, Bassett AR, Harding H, Galanty Y, Munoz-Martinez F, Metzakopian E, Jackson SP, Parts L. Nat Biotechnol. 2018 Nov 27. pii: nbt.4317. doi: 10.1038/nbt.4317. PubMed |
| The Cep57-pericentrin module organizes PCM expansion and centriole engagement. Watanabe K, Takao D, Ito KK, Takahashi M, Kitagawa D. Nat Commun. 2019 Feb 25;10(1):931. doi: 10.1038/s41467-019-08862-2. PubMed |
| Establishment of a system for screening autophagic flux regulators using a modified fluorescent reporter and CRISPR/Cas9. Yazawa R, Nishida Y, Aoyama S, Tanida I, Miyatsuka T, Suzuki L, Himuro M, Haruna H, Takubo N, Shimizu T, Watada H. Biochem Biophys Res Commun. 2019 Aug 27;516(3):686-692. doi: 10.1016/j.bbrc.2019.06.129. Epub 2019 Jun 26. PubMed |
| The transcriptional corepressor CBFA2T3 inhibits all-trans-retinoic acid-induced myeloid gene expression and differentiation in acute myeloid leukemia. Steinauer N, Guo C, Zhang J. J Biol Chem. 2020 Jul 3;295(27):8887-8900. doi: 10.1074/jbc.RA120.013042. Epub 2020 May 20. PubMed |
Intracellular arginine-dependent translation sensor reveals the dynamics of arginine starvation response and resistance in ASS1-negative cells.
Rogers LC, Zhou J, Baker A, Schutt CR, Panda PK, Van Tine BA.
Cancer Metab. 2021 Jan 21;9(1):4. doi: 10.1186/s40170-021-00238-9.
PubMed
Associated Plasmids |
| Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages. Hojo H, Saito T, He X, Guo Q, Onodera S, Azuma T, Koebis M, Nakao K, Aiba A, Seki M, Suzuki Y, Okada H, Tanaka S, Chung UI, McMahon AP, Ohba S. Cell Rep. 2022 Sep 6;40(10):111315. doi: 10.1016/j.celrep.2022.111315. PubMed |
| Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Jamal K, Galbiati A, Armenia J, Illuzzi G, Hall J, Bentouati S, Barrell D, Ahdesmaki M, O'Connor MJ, Leo E, Forment JV. Cancer Res Commun. 2022 Oct 21;2(10):1244-1254. doi: 10.1158/2767-9764.CRC-22-0119. eCollection 2022 Oct. PubMed |
| SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells. Zhang L, Hsu JI, Braekeleer ED, Chen CW, Patel TD, Martell AG, Guzman AG, Wohlan K, Waldvogel SM, Urya H, Tovy A, Callen E, Murdaugh R, Richard R, Jansen S, Vissers L, de Vries BBA, Nussenzweig A, Huang S, Coarfa C, Anastas JN, Takahashi K, Vassiliou G, Goodell MA. bioRxiv [Preprint]. 2024 Jan 17:2023.08.31.555634. doi: 10.1101/2023.08.31.555634. PubMed |
| Saturation genome editing of DDX3X clarifies pathogenicity of germline and somatic variation. Radford EJ, Tan HK, Andersson MHL, Stephenson JD, Gardner EJ, Ironfield H, Waters AJ, Gitterman D, Lindsay S, Abascal F, Martincorena I, Kolesnik-Taylor A, Ng-Cordell E, Firth HV, Baker K, Perry JRB, Adams DJ, Gerety SS, Hurles ME. Nat Commun. 2023 Dec 6;14(1):7702. doi: 10.1038/s41467-023-43041-4. PubMed |
| XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients. Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, Zanella ER, Borgato S, Corti G, di Blasio L, Somale D, Vara-Messler M, Galimi F, Sassi F, Lupo B, Catalano I, Pinnelli M, Viviani M, Sperti L, Mellano A, Ferrero A, Zingaretti CC, Puliafito A, Primo L, Bertotti A, Trusolino L. Nat Commun. 2024 Aug 29;15(1):7495. doi: 10.1038/s41467-024-51909-2. PubMed |
| Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. Illuzzi G, Galbiati A, Staniszewska AD, Hanson R, Michaloglou C, Cooke SL, Uznanska K, Bialecka M, Solarczyk K, Dev HS, Massie CE, Albertella MR, Leo E, Forment JV, O'Connor MJ. NAR Cancer. 2025 Oct 7;7(4):zcaf035. doi: 10.1093/narcan/zcaf035. eCollection 2025 Dec. PubMed |
| CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer. Otero-Rosales M, Alvarez-Gonzalez M, Pazos I, de Luxan-Delgado B, Del Marro S, Pozo-Agundo E, Rodriguez-Santamaria M, Lopez-Fernandez A, Corte-Torres D, Granda-Diaz R, Alvarez-Teijeiro S, Fernandez-Vega I, Lorz C, Garcia-Escudero R, Rodrigo JP, Tzelepis K, Vassiliou G, Ferrer I, Alvarez-Fernandez M, Garcia-Pedrero JM, Hermida-Prado F. Signal Transduct Target Ther. 2025 Nov 6;10(1):363. doi: 10.1038/s41392-025-02452-z. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.